NCT01716572

Brief Summary

The researchers will investigate whether erythromycin infusion is better than gastric lavage prior to emergency endoscopy to improve the quality of examination in patients with upper gastrointestinal bleeding.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
122

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Feb 2012

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 28, 2012

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 30, 2012

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

October 8, 2015

Status Verified

October 1, 2015

Enrollment Period

3.6 years

First QC Date

June 28, 2012

Last Update Submit

October 7, 2015

Conditions

Keywords

Upper gastrointestinal bleedingEndoscopyErythromycinGastric lavage

Outcome Measures

Primary Outcomes (1)

  • Visual quality of endoscopy

    To assess the visual quality of endoscopy the investigators will use the Avgerinos' score modified by Frossard (Gastroenterology 2002;123:17-23). An score from 0 to 2(0 worst vision, where \< 25% of the surface was visible. 1, 25-75% visible and 2 \>75% visible) was derived from analysis of each area (fundus, body, antrum and bulbus). A score of 6 or greater is considered as a clear stomach, and a score of 5 or lower was considered as a full stomach.

    The endoscopy will be recorded and subsequently it will be evaluated by two endoscopists unaware of the cleaning strategy. The recording's evaluation will be made within the first 30 days after endoscopy

Secondary Outcomes (6)

  • need for a second-look endoscopy

    within the first 30 days after endoscopy

  • need of blood transfusion

    within 30 days after endoscopy

  • number of adverse events as a measure of safety and tolerability

    within the first 30 days after endoscopy

  • length of hospitalisation

    within the first 30 days after endoscopy

  • length of endoscopic procedure

    within the first 30 days after endoscopy

  • +1 more secondary outcomes

Study Arms (2)

gastric lavage

ACTIVE COMPARATOR

gastric lavage by nasogastric tube with 1 liter saline before the endoscopy

Procedure: gastric lavage

erythromycin

ACTIVE COMPARATOR

administration of 250mgr of erythromycin before the endoscopy

Drug: Erythromycin

Interventions

Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy

Also known as: Pantomicina Intravenosa
erythromycin

gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy

gastric lavage

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • recent hematemesis (\<12 hours)

You may not qualify if:

  • macrolides allergy
  • pregnancy or lactation
  • treatment with terfenadine, astemizole or cyclosporine
  • prior gastrectomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, 08907, Spain

Location

Related Publications (7)

  • Frossard JL, Spahr L, Queneau PE, Giostra E, Burckhardt B, Ory G, De Saussure P, Armenian B, De Peyer R, Hadengue A. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology. 2002 Jul;123(1):17-23. doi: 10.1053/gast.2002.34230.

    PMID: 12105828BACKGROUND
  • Coffin B, Pocard M, Panis Y, Riche F, Laine MJ, Bitoun A, Lemann M, Bouhnik Y, Valleur P; Groupe des endoscopistes de garde a l'AP-HP. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc. 2002 Aug;56(2):174-9. doi: 10.1016/s0016-5107(02)70174-0.

    PMID: 12145593BACKGROUND
  • Carbonell N, Pauwels A, Serfaty L, Boelle PY, Becquemont L, Poupon R. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol. 2006 Jun;101(6):1211-5. doi: 10.1111/j.1572-0241.2006.00582.x.

    PMID: 16771939BACKGROUND
  • Pateron D, Vicaut E, Debuc E, Sahraoui K, Carbonell N, Bobbia X, Thabut D, Adnet F, Nahon P, Amathieu R, Aout M, Javaud N, Ray P, Trinchet JC; HDUPE Collaborative Study Group. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med. 2011 Jun;57(6):582-9. doi: 10.1016/j.annemergmed.2011.01.001. Epub 2011 Feb 17.

    PMID: 21333385BACKGROUND
  • Barkun AN, Bardou M, Martel M, Gralnek IM, Sung JJ. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc. 2010 Dec;72(6):1138-45. doi: 10.1016/j.gie.2010.08.011.

    PMID: 20970794BACKGROUND
  • Winstead NS, Wilcox CM. Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007 Nov 15;26(10):1371-7. doi: 10.1111/j.1365-2036.2007.03516.x. Epub 2007 Sep 10.

    PMID: 17848180BACKGROUND
  • Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010 Jan 19;152(2):101-13. doi: 10.7326/0003-4819-152-2-201001190-00009.

    PMID: 20083829BACKGROUND

MeSH Terms

Conditions

Gastrointestinal HemorrhageHematemesis

Interventions

ErythromycinGastric Lavage

Condition Hierarchy (Ancestors)

Gastrointestinal DiseasesDigestive System DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsVomitingSigns and Symptoms, DigestiveSigns and Symptoms

Intervention Hierarchy (Ancestors)

MacrolidesPolyketidesLactonesOrganic ChemicalsTherapeutic IrrigationInvestigative Techniques

Study Officials

  • Antonio Soriano, M D, Ph D

    Hospital Universitari de Bellvitge

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician Doctor

Study Record Dates

First Submitted

June 28, 2012

First Posted

October 30, 2012

Study Start

February 1, 2012

Primary Completion

September 1, 2015

Study Completion

December 1, 2015

Last Updated

October 8, 2015

Record last verified: 2015-10

Locations